Voriconazole pharmacokinetic models - comparing two softwares
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00136390" target="_blank" >RIV/00216224:14160/24:00136390 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Voriconazole pharmacokinetic models - comparing two softwares
Original language description
Voriconazole (VRC), a second-generation azole antifungal, is the first choice for the treatment of Aspergillus infections. VRC is a drug with significant intra- and inter-individual variability, therapeutic monitoring (TDM) of voriconazole is therefore recommended for most patients according to currently valid international standards. However, the full potential of TDM in clinical practice can be exploited based on pharmacokinetic models with high predictive power that are not currently available for specific patient populations. The aim is to compare two pharmacokinetic models in the context of measured plasma concentrations of VRC in real patients.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30500 - Other medical sciences
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů